Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + pantoprazole
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of metformin, a biguanide antihyperglycemic agent used for type 2 diabetes mellitus, and pantoprazole, a proton pump inhibitor (PPI) used for acid-related gastrointestinal conditions. This combination may be prescribed when patients with diabetes also have acid-related conditions or experience gastrointestinal side effects from metformin. Studies show that pantoprazole does not impair metformin's effectiveness and may actually improve beta cell function and reduce metformin's gastrointestinal side effects.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ATP4A (Potassium–transporting ATPase alpha chain 1)ND1 (Mitochondrial electron transport chain complex I)OCT1 (Organic cation transporter 1)OCT2 (Organic cation transporter 2)OCT3 (Organic cation transporter 3)
Beyond the preview
Go deeper on metformin + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + pantoprazole.